Drug Profile
AVE 9103
Latest Information Update: 04 Mar 2003
Price :
$50
*
At a glance
- Originator OSI Pharmaceuticals
- Developer Aventis
- Class
- Mechanism of Action LDL receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Hypercholesterolaemia
Most Recent Events
- 04 Mar 2003 This compound is still in active development
- 28 Dec 2002 No development reported - Preclinical for Hypercholesterolaemia in USA (unspecified route)
- 01 May 2001 Preclinical development for Hypercholesterolaemia in USA (Unknown route)